URGN
UroGen Pharma·NASDAQ
--
--(--)
--
--(--)
7.41 / 10
Outperform
Analyst coverage is overwhelmingly bullish (Strong Buy 100% from 2 analysts), and fund-flow sentiment is robust at 7.74/10. Although overall fund-trend is negative, small- and medium-scale inflows are positive, hinting at retail or nimble-money accumulation. The strong analyst conviction aligns with the technical upswing, reinforcing a buy-the-dip approach while monitoring large-block flows.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-23
InstitutionD. Boral Capital
Times predicted16
Historical Win Rate50.0%
Is money flowing into or out of URGN?
- URGN holds a Bullish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 7.41/10 (Outperform).
